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Abstract
Modulation of synaptic transmission in the spinal cord dorsal horn is thought to be involved in the development
and maintenance of different pathological pain states. The proinflamatory cytokine, tumor necrosis factor a (TNFa),
is an established pain modulator in both the peripheral and the central nervous system. Up-regulation of TNFa
and its receptors (TNFR) in dorsal root ganglion (DRG) cells and in the spinal cord has been shown to play an
important role in neuropathic and inflammatory pain conditions. Transient receptor potential vanilloid 1 (TRPV1)
receptors are known as molecular integrators of nociceptive stimuli in the periphery, but their role on the spinal
endings of nociceptive DRG neurons is unclear. The endogenous TRPV1 receptor agonist N-oleoyldopamine (OLDA)
was shown previously to activate spinal TRPV1 receptors. In our experiments the possible influence of TNFa on
presynaptic spinal cord TRPV1 receptor function was investigated. Using the patch-clamp technique, miniature exci-
tatory postsynaptic currents (mEPSCs) were recorded in superficial dorsal horn neurons in acute slices after incuba-
tion with 60 nM TNFa. A population of dorsal horn neurons with capsaicin sensitive primary afferent input
recorded after the TNFa pretreatment had a basal mEPSC frequency of 1.35 ± 0.20 Hz (n = 13), which was signifi-
cantly higher when compared to a similar population of neurons in control slices (0.76 ± 0.08 Hz; n = 53; P < 0.01).
In control slices application of a low concentration of OLDA (0.2 uM) did not evoke any change in mEPSC fre-
quency. After incubation with TNFa, OLDA (0.2 uM) application to slices induced a significant increase in mEPSC
frequency (155.5 ± 17.5%; P < 0.001; n = 10). Our results indicate that TNFa may have a significant impact on noci-
ceptive signaling at the spinal cord level that could be mediated by increased responsiveness of presynaptic TRPV1
receptors to endogenous agonists. This could be of major importance, especially during pathological conditions,
when increased levels of TNFa and TNFR are present in the spinal cord.
Background
The cytokine, tumor necrosis factor a (TNFa), is now
well established as a pain modulator in both the periph-
eral and central nervous systems [1]. There is now
mounting evidence of TNFa involvement in inflamma-
tory, neuropathic and cancer-related pain [2]. Several
studies have shown a correlation between the level of
TNFa expression and the development of allodynia or
hyperalgesia [2-5]. Besides increased local TNFa synth-
esis and release during peripheral inflammation, TNFa
up-regulation has also been demonstrated in dorsal root
ganglion (DRG) neurons [6-8] and spinal cord [3,9,10]
in experimental models of peripheral neuropathy,
including chronic constriction injury (CCI), L5 spinal
nerve transection or sciatic nerve crush. It has been sug-
gested that during neuropathy or peripheral inflamma-
tion TNFa could be released in the spinal cord mainly
from activated glial cells [9-11].
The effect of TNFa is mediated by two receptors:
TNFR1 (p55) and TNFR2 (p75). Both receptors have been
detected in DRG and spinal cord neurons [12,13]. In dif-
ferent peripheral neuropathy models, TNFR1/2 receptors
are up-regulated in DRG neurons [14-16] and TNFR1 in
the spinal cord dorsal horn (DH) [10]. Later studies loca-
lized TNFR2 expression exclusively in non-neuronal DRG
cells after lipopolysaccharide (LPS) treatment [17] or after
inflammation induced by complete Freund’s adjuvant
(CFA) [18]. It was recently demonstrated that TNFR2
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receptors are crucial for the development of heat hyperal-
gesia in a cancer-related pain model in mice [4].
Nociceptive DRG neurons express transient receptor
potential vanilloid 1 (TRPV1) receptors, which are
localized on their peripheral and central endings [19].
In peripheral tissue they serve as molecular integrators
of nociceptive stimuli. However, the function of spinal
TRPV1 receptors is not fully understood. As tempera-
ture increases or pH decreases, which activate TRPV1
receptors in the periphery, do not occur in the spinal
cord, great effort was needed to detect possible endo-
genous activators of central TRPV1 receptors [20].
Recently, several lipids have been described as potential
endogenous agonists of TRPV1 receptors. Most of
them also activate cannabinoid receptors, similar to
anandamide (AEA, N-arachidonoylethanolamine),
which was one of the first substances suggested to act
as an endogenous TRPV1 receptor ligand [21]. AEA
has been shown to excite cutaneous C nociceptors via
TRPV1 receptors activation and to evoke nocifensive
behaviour after peripheral application in vivo [22].
Intrathecal AEA administration has been demonstrated
to have an analgesic effect, while higher concentrations
also evoke pain-related behavior [23]. Other potential
endogenous activators of TRPV1 receptors are pro-
ducts of lipoxygenases [24], omega-3 polyunsaturated
fatty acids [25] or unsaturated N-acyldopamines origin-
ally isolated from bovine striatum as N-arachidonoyl-
dopamine (NADA) [26]. Further analysis of striatal
extracts resulted in the identification of, among other
acyldopamines, N-oleoyldopamine (OLDA), which
induces thermal hyperalgesia after intraplantar applica-
tion and possesses a high potency of putative endova-
nilloid in mobilization of intracellular calcium in
TRPV1-transfected cells [27]. Unlike NADA, OLDA is
only a weak ligand for rat CB1 receptors; but is recog-
nized by the anandamide membrane transporter while
being a poor substrate for fatty-acid amide hydrolase
(FAAH) [27]. Behavioral experiments have shown ther-
mal hyperalgesia following intrathecal OLDA adminis-
tration [28]. Our previous electrophysiological
recordings in spinal cord slices demonstrated that
application of 10 μM OLDA solution increases mEPSC
frequency in superficial DH neurons due to specific
TRPV1 receptor activation, as demonstrated by TRPV1
antagonists (SB366791, BCTC) application [28]. The
concentration of OLDA needed to activate TRPV1
receptors decreased dramatically from 10 μM under
control conditions to 0.2 μM after PKC activation, pre-
treatment with the inflammatory mediator bradykinin,
or in a model of peripheral inflammation [28].
It has been shown previously that TRPV1 receptor
expression and sensitivity to capsaicin may be modu-
lated by TNFa pretreatment [4,29-31]. In our
experiments we have studied modulation of spinal cord
presynaptic TRPV1 receptor function by TNFa. We
have recorded the frequency of mEPSCs from superficial
dorsal horn neurons in spinal cord slices in order to
investigate the effect of acute slice incubation with cyto-
kine TNFa on TRPV1 receptor activation by the endo-
genous agonist, OLDA.
Methods
Acute spinal cord slices were prepared from male Wis-
tar rats on postnatal days P19 to P23, as was described
previously [28]. After anesthesia with pentobarbital
sodium (90 mg/kg), the lumbar spinal cord was removed
and immersed in oxygenated ice-cold dissection solution
containing (in mM): 95 NaCl, 1.8 KCl, 7 MgSO4,
0.5 CaCl2, 1.2 KH2PO4, 26 NaHCO3, 25 D-glucose,
50 sucrose. The spinal cord was fixed to a vibratome
stage using cyanoacrylate glue (Leica, VT 1000 S, Ger-
many) in a groove between two agar blocks. Acute
transverse slices 300 - 350 μm thick were cut, incubated
in the dissection solution for 30 min at 33°C and then
stored in a recording solution at room temperature and
allowed to recover for 1 h before the electrophysiologi-
cal experiments. Recording solution contained (in mM):
127 NaCl, 1.8 KCl, 1.2 KH2PO4, 2.4 CaCl2, 1.3 MgSO4,
26 NaHCO3, 25 D-glucose. For the actual measurement,
slices were transferred into a recording chamber that
was perfused continuously with recording solution at a
rate >2 ml/min. All extracellular solutions were satu-
rated with carbogen (95% O2, 5% CO2) during the
whole process.
Patch-clamp recordings were made from individual
DH neurons visualized using a differential interference
contrast (DIC) microscope (Leica, DM LFSA, Germany)
equipped with an infrared-sensitive camera (IR camera
Hitachi KP-200P, Japan) with a standard TV/video
monitor (Hitachi VM-172, Japan). Patch pipettes were
pulled from borosilicate glass tubing (Rückl Glass, Otvo-
vice, Czech Republic). When filled with intracellular
solution, they had resistances of 3.5 - 7.0 MΩ. The
intracellular pipette solution contained (in mM): 125 glu-
conic acid lactone, 15 CsCl, 10 EGTA, 10 HEPES,
1 CaCl2, 2 Na2ATP, 0.5 NaGTP and was adjusted to pH
7.2 with CsOH. Voltage-clamp recordings in the whole-
cell configuration were performed with an AxoPatch
1 D amplifier (Molecular Devices, USA) at room tem-
perature (21°C - 24°C). Whole-cell responses were low-
pass filtered at 2 kHz and digitally sampled at 10 kHz.
The series resistance of neurons was routinely compen-
sated by 80% and was monitored during the whole
experiment. AMPA receptor-mediated mEPSCs were
recorded from superficial DH neurons in laminae I and
II, clamped at -70 mV in the presence of 10 μM bicu-
culline, 5 μM strychnine and 0.5 μM tetrodotoxin
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(TTX). The software package pCLAMP version 9.0
(Axon Instruments, Inc., Foster City, CA, USA) was
used for data acquisition and subsequent off-line analy-
sis. Neurons with capsaicin-sensitive primary afferent
input were identified by the increase of mEPSC fre-
quency (> 20%) following capsaicin (0.2 μM) administra-
tion at the end of the experimental protocol.
All drugs used in this study were of analytical grade
and purchased from Sigma-Aldrich (Prague, Czech
Republic) or Tocris Bioscience (Bristol, UK). TNFa was
dissolved in 0.1% BSA; capsaicin and OLDA were dis-
solved in dimethylsulfoxide (DMSO), which had a con-
centration < 0.1% in the final solution.
Data segments of 2 min duration were analyzed for
each experimental condition. Only mEPSCs with an
amplitude of 5 pA or greater (which corresponded to at
least twice the noise level) were included in the fre-
quency analysis. In the case of amplitude analysis, the
same events and data segments were used. Data are
expressed as means ± standard error of the mean
(SEM). Some data were normalized as a percentage of
the control values (100%). One-way ANOVA and one-
way ANOVA repeated measures followed by post hoc
test (Bonferroni) were used for statistical comparisons
and P < 0.05 was considered to be statistically signifi-
cant. A Kolmogorov-Smirnov test was used to evaluate
statistical significance for cumulative data.
All experiments were approved by the local Institu-
tional Animal Care and Use Committee and were con-
sistent with the guidelines of the International
Association for the Study of Pain, the National Institutes
of Health Guide for the Care and Use of Laboratory
Animals and the European Communities Council Direc-
tive of 24 November 1986 (86/609/EEC).
Results
Spinal cord slices were incubated in 60 nM TNFa for at
least 2 h before the actual experiments. Recordings from
16 neurons in slices incubated with TNFa were made
altogether. The application of the endogenous TRPV1
receptor agonist OLDA (0.2 μM) increased mEPSC fre-
quency in 10 of the 16 DH neurons tested. At the end
of each recording, 0.2 μM capsaicin was administered to
confirm input from nociceptive primary afferents
expressing TRPV1 receptors. Capsaicin is known to
increase mEPSC frequency in superficial DH neurons in
a concentration-dependent manner via presynaptic
TRPV1 receptors localized on central terminals of DRG
neurons [28,32]. Capsaicin application in our experi-
ments increased mEPSC frequency in 13 of the 16 DH
neurons by 372.6 ± 78.1%. All 10 neurons that
responded to the OLDA application were also respon-
sive to the capsaicin application (10 out of 13).
Figure 1 Application of a low concentration of OLDA (0.2 μM)
did not change mEPSC frequency in a superficial dorsal horn
neuron, as recorded under control conditions (A), while a
significant increase in mEPSC frequency was observed in slices
incubated with the cytokine TNFa (60 nM; B). The amplitude of the
mEPSCs was not changed after OLDA application in this neuron (C).
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We have shown previously that application of a low
concentration of OLDA (0.2 μM) does not evoke any
changes under control conditions [28]. Basal mEPSC
frequency in the control recordings established as 100%
did not change during OLDA (0.2 μM) application
(99.6 ± 4.0%; n = 25; Figs. 1A and 2). In the actual mea-
surements, the low concentration of OLDA solution
(0.2 μM) applied under the same experimental condi-
tions increased the mEPSC frequency to 155.5 ± 17.5%
(P < 0.001; n = 10) in acute spinal cord slices incubated
with TNFa, when compared to the control values before
the OLDA application (Figs. 1B and 2). Capsaicin appli-
cation in this population of neurons increased mEPSC
frequency to a higher level (387.4 ± 109.5%; n = 10)
than did the endogenous agonist. Increase in the abso-
lute mEPSC frequency during OLDA application in neu-
rons incubated with TNFa (1.78 ± 0.22 Hz) was also
statistically significantly different from the control
mEPSC frequency before OLDA application (1.21 ± 0.17
Hz; P < 0.01; Fig. 3) and from the basal mEPSC fre-
quency recorded in control slices without the TNFa
pretreatment (0.76 ± 0.13 Hz; n = 25; P < 0.001). The
basal mEPSC frequency (1.21 ± 0.17 Hz) recorded in
neurons in TNFa incubated slices was significantly
higher (P < 0.05) when compared to the basal mEPSC
frequency (0.76 ± 0.13 Hz) recorded from neurons in
control slices (Fig. 3).
Incubation of spinal cord slices with TNFa did not
change the average mEPSC amplitude in the recorded
neurons during OLDA (23.02 ± 2.98 pA; n = 10) appli-
cation compared to control values before its application
(21.98 ± 2.50 pA) and compared to mEPSC amplitude
in neurons from control slices (24.12 ± 1.23 pA;
n = 25). This is documented also by a cumulative ampli-
tude distribution (Fig. 1C).
All recorded superficial DH neurons with input from
TRPV1 receptors containing primary nociceptive fibres
incubated with TNFa had a significantly higher basal
frequency of mEPSCs (1.35 ± 0.20 Hz; n = 13; P < 0.01)
compared to the same population of control neurons
(0.76 ± 0.08 Hz; n = 53) [28]. In contrast, neurons with-
out input from primary afferents containing TRPV1
receptors and incubated with TNFa had a lower basal
mEPSC frequency (1.02 ± 0.56 Hz; n = 3) compared to
the same population of neurons in control slices (2.07 ±
0.39 Hz; n = 23; P > 0.05). Average basal mEPSC fre-
quency of all of the recorded neurons was not different
between the neurons recorded in slices incubated with
TNFa (1.28 ± 0.18; n = 16) and in control slices (1.13 ±
0.14; n = 76). While the number of recorded neurons
without presynaptic input from capsaicin sensitive fibres
was very low (n = 3), we cannot deduce from our results
if there was any significant effect of TNFa on the
mEPSC frequency in this population of neurons. There
was no change in average mEPSC amplitude in DH neu-
rons with input from capsaicin sensitive and insensitive
primary afferent fibres incubated with TNFa compared
to the appropriate populations of neurons in control
slices without TNFa incubation.
Discussion
Application of a low concentration (0.2 μM) of the
TRPV1 endogenous agonist OLDA does not evoke any
changes in mEPSC frequency recorded from superficial
Figure 2 Application of a low concentration of OLDA solution
(0.2 μM) did not change mEPSC frequency in neurons, as
recorded under control conditions (n = 25). The same OLDA
application significantly increased mEPSC frequency in neurons
recorded in spinal cord slices incubated with TNFa (60 nM; n = 10;
***P < 0.001). Values are given in percent of the corresponding
mEPSC frequency before the OLDA application (100%).
Figure 3 In control slices without TNFa pretreatment, OLDA
application did not induce a significant change in mEPSC
frequency. Incubation with the cytokine TNFa increased basal
mEPSC frequency (n = 10; *P < 0.05) in a population of DH neurons
with capsaicin-sensitive primary afferent fibre inputs, when
compared to recordings from control slices without TNFa
incubation (n = 25). The high statistical significance of the mEPSC
frequency increase during OLDA application in neurons after TNFa
incubation was also evident without data normalization (**P < 0.01).
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dorsal horn neurons under control conditions without
TNFa incubation [28]. In the present experiments we
have demonstrated that TNFa pretreatment significantly
increases sensitivity to OLDA application in 10 (~60%)
out of the total of 16 recorded neurons. Our hypothesis
assumes that this effect is mediated by TNFR-induced
modulation of TRPV1 receptors. It thus seems plausible
to suggest that both TRPV1 and TNFR receptors
have to be expressed in the presynaptic endings for this
effect to be present. Out of the 16 neurons, 3 did not
respond to the capsaicin application, implying a lack of
TRPV1 receptors in these neurons. In the population of
13 neurons responding with increased mEPSC frequency
to the capsaicin application, 3 neurons did not respond
to the OLDA application, possibly due to an absence of
TNFR receptors, while 10 out of the 13 neurons (~77%)
responded to the OLDA application.
The importance of TNFR1 receptors for development
of neuropathic pain syndromes appears to be well docu-
mented. TNFR1 receptors are not only present on DRG
neuronal bodies but also at numerous central branches
of DRG neurons in the spinal cord dorsal horn [33]. A
crucial role of TNFR1 receptor activation in the experi-
mental model of neuropathic pain using chronic con-
striction injury of the sciatic nerve has been
demonstrated using neutralizing antibodies to the
TNFR1 receptor to reduce thermal hyperalgesia and
mechanical allodynia [34]. Ventral root transection
accompanied with mechanical allodynia and thermal
hyperalgesia increases immunoreactivity of TNFa and
TNFR1 receptors in ipsilateral DRG and bilaterally in
the spinal cord DH [35]. A role for TNFR2 receptors in
heat hyperalgesia has been implicated in a model of can-
cer pain where TRPV1 protein up-regulation in DRG
neurons is attenuated in TNFR2 knock-out mice [4].
Coexpression of mRNA for TNFR1 and TRPV1 recep-
tors [17] and colocalization of TNFR1 and TRPV1
immunoreactivity [29] in DRG neurons has been
reported. Long-term application of TNFa (48 h)
increases the number of TRPV1 immunopositive DRG
neurons in culture. This increased expression of TRPV1
receptors is dependent on ERK (extracellular regulated
kinase = p44/p42 MAP kinase) activation and TNFR1
receptors, as has been shown using DRG neurons iso-
lated from TNFR1-/- knock out mice [29]. In contrast,
TRPV1 receptor up-regulation in DRG neurons is
dependent on TNFR2 receptors in tumor-bearing mice
[4]. The increase of TRPV1 protein level after TNFa
application correlates well with a previous demonstra-
tion of an increased number of DRG neurons labeled
with cobalt staining after TRPV1 receptor activation by
capsaicin in neurons cultivated with TNFa [31]. The
increased cobalt staining in these experiments is depen-
dent on the activation of cyclooxygenase, in contrast to
other findings [29]. The change in capsaicin sensitivity
after TNFa treatment is rapid, with an increase after
4 h of incubation [31]. TNFa stimulation of cultured
DRG neurons produces an increase in TRPV1 receptor
protein level after 1 and 2 h of incubation [4]. In tri-
geminal neurons, TNFa application increases CGRP
release after capsaicin stimulation [30]. In these experi-
ments, doubling of TRPV1 receptor mRNA was evident
only after 30 min of TNFa incubation.
In our experiments the cell bodies of DRG neurons
were absent during the TNFa incubation of spinal cord
slices. The increased sensitivity to OLDA application
was thus most likely mediated through TRPV1 receptors
phosphorylation and/or their translocation from the
cytoplasm to the presynaptic ending membrane.
Increased sensitivity of TRPV1 receptors to agonists due
to PKC- or PKA-mediated phosphorylation has been
repeatedly demonstrated [36]. Also, TNFa incubation
(5 min) has been shown to have a fast potentiating
effect on capsaicin-stimulated increases in intracellular
accumulation of Ca2+ ions [30]. Capsaicin-evoked cur-
rents are robustly potentiated after only 60 s of TNFa
application in cultured DRG neurons, and this effect is
mediated via activation of PKC or p38/MAP kinase [4].
It is thus probable that the effect of TNFa on TRPV1
receptors is mediated by similar pathways in our experi-
ments, while transcriptional changes may also play an
important role under pathological conditions in vivo,
where spinal TNFa has been shown to play an impor-
tant role [37].
In our experiments we did not record any significant
change in the mEPSC amplitude, which is in good
agreement with previous findings [38,39]. However,
postsynaptic changes due to TNFa incubation could
have most likely also occurred. Regulation of NMDA
receptor activity or AMPA receptor expression by
TNFa has been described for other areas of the CNS
[40]. Neutralization of TNFa in the rostral ventromedial
medulla (RVM), a major component of brainstem des-
cending pain modulatory circuitry, attenuates phosphor-
ylation of NMDA receptor NR1 subunits [41]. TNFa
induces enhancement of synaptic efficacy by increasing
surface AMPA receptor expression in hippocampal neu-
rons [42]. It has also been documented that TNFa
enhances spontaneous EPSCs and potentiates AMPA-
and NMDA-mediated currents due to up-regulation of
spinal chemokine MCP-1 and activation of its post-
synaptic CCR2 receptors in DH neurons [43]. Acute
TNFa application in spinal cord slices increases the fre-
quency of spontaneous EPSCs in some lamina II neu-
rons (8 of 14 neurons), and also increases AMPA- (5 of
9 neurons) and NMDA- (all recorded neurons) stimu-
lated currents [38]. Increase of sEPSC and mEPSC fre-
quencies during acute application of TNFa has been
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confirmed by Youn et al. (2008) [39], together with the
observation of a TNFa-stimulated increase in sponta-
neous IPSC frequency. From previously published
results and our study, it is evident that TNFa- induced
modulation of excitatory synaptic transmission in the
spinal cord dorsal horn is a complex process mediated
by fast mechanisms and by slow transcription-dependent
changes.
Our results suggest that increased levels of TNFa and
its receptors under pathological conditions may have
considerable impact on the function of spinal cord
TRPV1 receptors. The resulting increased sensitivity of
TRPV1 receptors to endogenous agonist may signifi-
cantly modulate nociceptive synaptic transmission in the
spinal cord dorsal horn. While additional experiments
are needed to elucidate the specific mechanisms
involved in TNFa-induced modulation of TRPV1 recep-
tor function, it is clear that these results may also point
to new targets for pain therapy.
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